<DOC>
	<DOCNO>NCT02715362</DOCNO>
	<brief_summary>Intravenous infusion CART cell treatment solid tumor may suitable choice . Because intravenous infusion , T cell first enter blood circulation , number T cell accumulate tumor site limit , probability high CART cell contact normal tissue target protein express , lead potential off-target side effect . In study , CART cell infuse body mediate method transcatheter arterial infusion ( TAI ) , one kind tumor intervention therapy pathway . We hope mean could improve local CAR-T cell numbers，meanwhile reduce potential side effect .</brief_summary>
	<brief_title>A Study GPC3 Redirected Autologous T Cells Advanced HCC</brief_title>
	<detailed_description>Patients treat leukapheresis peripheral blood mononuclear cell purify . T cell activate re-engineered express chimeric antigen receptor ( CARs ) specific GPC3 . Cells expanded culture return participant transcatheter arterial infusion dose . ( 1-10 ) ×106 CAR positive T cells/kg . The cell perfusion process would last 15min 2 h via ambulatory infusion pump . A single dose 1.5 grams/m2 cyclophosphamide give two day CART cell infusion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>GPC3 expression positive histologically confirm hepatocellular carcinoma ; Aged 18 69 ; Persistent cancer least one prior standard care chemotherapy , willing surgery suitable surgery patient ; Life expectancy great 6 month ; Satisfactory organ bone marrow function define follow : ( 1 ) creatinine &lt; 1.5mg/dl ; ( 2 ) albumin &gt; 2 ; ( 3 ) cardiac ejection fraction &gt; 55 % ; ( 4 ) hemoglobin &gt; 9g/dl , bilirubin 2.0×the institution normal upper limit ; Without bleed disorder coagulation disorder ; Dont allergy Radiocontrast agent ; Birth control ; Adequate venous access apheresis , contraindication leukapheresis ; Voluntary inform consent give . Pregnant lactating woman ; Concurrent use systemic steroid . Recent current use inhale steroid exclusionary ; Patients situation : ( 1 ) 30 day apheresis still period antitumor drug observation ; ( 2 ) patient dont recuperate earlier acute adverse influence bring treatment accept ; Four week recruit accept radiation therapy ; Previously treatment gene therapy product ; Feasibility assessment screen demonstrates &lt; 30 % transduction target lymphocytes , insufficient expansion ( &lt; 5fold ) response CD3/CD28 costimulation ; Any serious , uncontrolled disease ( include , limit , unstable angina pectoris , congestive heart failure , grade III IV cardiac disease , serious arrhythmia , liver kidney disorder metabolic disease , CNS diseases ) ; Patient severe acute hypersensitive reaction ; Taking part clinical trial ; Study leader considers suitable tiral .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>immunotherapy GPC3 CAR-T HCC</keyword>
</DOC>